Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Castle Biosciences Inc (NQ: CSTL ) 33.15 -1.52 (-4.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Castle Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients October 29, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Participate in Upcoming Investor Conferences October 28, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors October 20, 2024 From Castle Biosciences Inc. Via Business Wire Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential October 16, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 October 14, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin October 11, 2024 From Castle Biosciences Inc. Via Business Wire New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions October 09, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas October 02, 2024 From Castle Biosciences Inc. Via Business Wire New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma September 27, 2024 From Castle Biosciences Inc. Via Business Wire New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus September 23, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year September 16, 2024 From Castle Biosciences Inc. Via Business Wire DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms September 11, 2024 From Castle Biosciences Inc. Via Business Wire Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma September 05, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Participate in Upcoming Investor Conferences August 28, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Reports Second Quarter 2024 Results August 05, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference July 30, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma July 22, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 July 15, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Honored with Top Workplaces Awards July 11, 2024 From Castle Biosciences Inc. Via Business Wire Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test June 24, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner June 14, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance May 30, 2024 From Castle Biosciences Inc. Via Business Wire New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis May 29, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference May 15, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 May 14, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution” May 10, 2024 From Castle Biosciences Inc. Via Business Wire Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result May 08, 2024 From Castle Biosciences Inc. Via Business Wire DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck May 03, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Reports First Quarter 2024 Results May 02, 2024 From Castle Biosciences Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
